How do I check Medication Monitoring when issuing high-risk drugs?

Modified on Tue, 21 Apr at 10:00 AM

This check is still part of our prescribing system, however we now recommend you use our proactive prescribing checks we have developed to proactively check for monitoring and other potential issues - Prescribing Instructions: Proactive Prescribing Checks

This video explains how the medication monitoring checks protocol works when issuing high-risk drugs:

This is the list of medication monitoring that is checked by this protocol:

ACE inhibitor or ARB
ADHD Medication
Alfacalcidol
Allopurinol / Feboxustat
Amiodarone
Anti-hypertensive (change or initiation)
Antimetabolites
Antiproliferative Immunosuppressants
Antipsychotic
Antithyroid Drugs
Apomorphine
Azathioprine
Azithromycin
Ciclosporin
Cinacalcet
Dapsone
Denosumab
Diabetes Medication (change or initiation)
Digoxin
DOAC
Dronedarone
Gold
Lefluonimide
Lipid Regulating Agent
Lithium
Loop Diuretic
Mercaptopurine
Mesalazine, Olsalazine or Balsalazide
Methotrexate
Midodrine
Minocycline
Mirabegron
Modafinil
Nitrofurantoin / Trimethoprim >6 months
Oral Retinoids
Other antineoplastic drugs
Penicillamine
Potassium Sparing Diuretics and Aldosterone Antagonists
Rifaximin
Sulfasalazine
Tacrolimus
Testosterone Replacement
Thyroid Medication
Thyroxine (change or initiation)
Valproate
Warfarin

Unless otherwise indicated, the check is for regular monitoring. Medication that requires annual monitoring is only prompted for restrictions once its 16 months since relevant tests were completed. This is to allow time for monitoring to take place at annual reviews first. Once patients reach 14m since tests were taken, they will be included in high risk drug monitoring invites. If a patient reaches 16m, they should have had multiple invites and so be appropriate to consider restricting access to medication.